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Abstract
Osteosarcoma (OS) is a rare tumor of the bone occurring mainly in
young adults accounting for 5% of all childhood cancers. Because
of the limited therapeutic options, there has been no survival
improvement for OS patients in the past 40 years. The epidermal
growth factor receptor (EGFR) is highly expressed in OS; however,
its clinical relevance is unclear. Here, we employed an autochtho-
nous c-Fos-dependent OS mouse model (H2-c-fosLTR) and human
OS tumor biopsies for preclinical studies aimed at identifying novel
biomarkers and therapeutic benefits of anti-EGFR therapies. We
show that EGFR deletion/inhibition results in reduced tumor
formation in H2-c-fosLTR mice by directly inhibiting the prolifera-
tion of cancer-initiating osteoblastic cells by a mechanism involv-
ing RSK2/CREB-dependent c-Fos expression. Furthermore, OS
patients with co-expression of EGFR and c-Fos exhibit reduced
overall survival. Preclinical studies using human OS xenografts
revealed that only tumors expressing both EGFR and c-Fos
responded to anti-EGFR therapy demonstrating that c-Fos can be
considered as a novel biomarker predicting response to anti-EGFR
treatment in OS patients.
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Introduction
Osteosarcoma (OS) is the most common primary tumor of the bone
originating from transformed mesenchymal cells (Mirabello et al,
2009). It predominantly occurs in young adults with about 400 new
cases diagnosed in the United States each year (Ottaviani & Jaffe,
2009). Due to the lack of major therapeutic progress, the 5-year
survival of OS patients did not significantly improve since the 1980s,
thus raising the need for novel treatment strategies (Ando et al,
2013).
To design better therapeutic options for OS patients, it is essen-
tial to understand the molecular pathogenesis of the disease. Muta-
tions of the tumor suppressor genes p53 and Rb are major known
events inducing osteosarcomagenesis (Marina et al, 2004). More-
over, overexpression of proto-oncogenes like c-Myc or c-Fos was
reported to play an essential role during bone tumor formation (Wu
et al, 1990; Gamberi et al, 1998). Transgenic mice expressing c-fos
under the control of the ubiquitously expressed H2kb promoter (H2-
c-fosLTR) develop bone tumors with 100% penetrance (Ruther et al,
1989; Grigoriadis et al, 1993). Previous studies reported that OS
formation in these mice depends on the expression of endogenous
c-fos and on the activation and stabilization of c-Fos protein via the
MAPK-regulated S6 kinase RSK2 (Wang et al, 1995; David et al,
2005).
Epidermal growth factor receptor (EGFR) expression occurs in
55–81% of all OS cases; however, its clinical relevance in OS
development is still controversial (Oda et al, 1995; Wen et al,
2007; Do et al, 2009; Wang et al, 2018). EGFR can control c-Fos
via the MAPK pathway, and changes in c-fos expression after
anti-EGFR treatment in cell lines have been suggested to predict
therapy success (Jimeno et al, 2006; Murphy & Blenis, 2006).
Interestingly, EGFR significantly correlates with ERK activation in
human OSs (Do et al, 2009). Moreover, we recently showed that
EGFR is essential in osteoblasts for bone development via ERK-
dependent regulation of IGF-1/mTOR signaling (Linder et al,
2018). Because of the relatively low incidence rate of OS, clinical
trials with inhibitors or antibodies against EGFR could not estab-
lish a clear therapeutic benefit in bone tumor formation, due to
low statistical power (for review, see Wang et al, 2014). Preclini-
cal studies with EGFR inhibitors, which were mainly performed
in vitro using human OS cell lines or immunodeficient xenograft
models, have reported contradictory results (Messerschmitt et al,
1 Department of Medicine I, Comprehensive Cancer Center, Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
2 Spanish National Cancer Research Center (CNIO), Madrid, Spain
3 Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria
4 Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
5 Center for Health & Bioresources, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria
6 LBI Applied Diagnostics, Vienna, Austria
*Corresponding author. Tel: +43-1-40160-57502; Fax: 43-1-40160-957502; E-mail: Sibilia-Office@meduniwien.ac.at
ª 2018 The Authors. Published under the terms of the CC BY 4.0 license EMBO Molecular Medicine 10: e9408 | 2018 1 of 15
Published online: October 25, 2018 
2008; Lee et al, 2012; Sevelda et al, 2015; Gvozdenovic et al,
2017).
In the present study, we aimed to understand the role of EGFR
during OS development using the autochthonous H2-c-fosLTR
mouse model and human OS tumor biopsies. Since EGFR can acti-
vate S6 and RSK2, we hypothesized that EGFR might act as the
upstream receptor inducing OS formation in H2-c-fosLTR mice. We
found that EGFR signaling is essential in osteoblasts for bone tumor
formation and progression. We also identified EGFR as the upstream
receptor regulating endogenous c-fos expression and stabilizing and
activating c-Fos protein via MAPK/CREB signaling. In addition, we
show that EGFR and c-Fos co-expression inversely correlate with OS
patient survival. These findings provide strong evidence that EGFR
and c-Fos expression levels could be used as powerful clinical
biomarkers to identify OS patients likely to benefit from anti-EGFR
therapy.
Results
EGFR is essential for c-Fos-dependent OS formation
In order to investigate the role of EGFR signaling in OS develop-
ment, we first analyzed Egfr and c-fos mRNA expression in normal
bones from wild-type (wt) and H2-c-fosLTR mice, as well as in OSs
from H2-c-fosLTR mice. Both Egfr and c-fos levels were significantly
elevated in OSs, whereas no genotype depending differences were
observed in normal bones (Fig EV1A and B). To assess whether
EGFR signaling is required for c-Fos-dependent bone tumors, we
genetically attenuated EGFR signaling by breeding H2-c-fosLTR mice
to mice carrying the hypomorphic Egfr waved-2 allele (Egfrwa2/wa2),
leading to reduced EGFR activation (Luetteke et al, 1994). H2-c-
fosLTR/Egfrwa2/wa2 mice developed significantly less and smaller
bone tumors, indicating that EGFR is essential for bone tumor initia-
tion (Fig 1A–C). Furthermore, serum levels of alkaline phosphatase
(ALP), a clinically used indirect OS biomarker (Ren et al, 2015a),
were also significantly reduced in H2-c-fosLTR/Egfrwa2/wa2 mice
(Fig 1D). To investigate whether pharmacological EGFR inhibition
would also show therapeutic benefits, we treated 2-month-old H2-c-
fosLTR/Egfrwt mice with visible OS, over a period of 5 months with
erlotinib (Fig EV1C). Inhibition of EGFR phosphorylation by erlo-
tinib (Fig EV1D) induced tumor stasis indicated by significantly
reduced tumor number, tumor size, and ALP serum levels, when
compared to vehicle-treated controls (Fig 1E–H). mRNA expression
analysis of OS from H2-c-fosLTR mice and from human OS from a
publicly available dataset [E-GEOD-39058 (Kelly et al, 2013)]
revealed that EGFR might get activated by an autocrine loop as
EGFR ligands were expressed both in mouse and human OS with
Hb-EGF being the highest (Fig EV1E and F). In line, OSs from H2-c-
fosLTR mice showed significantly elevated expression of Hb-EGF
and TGFa as compared to normal bones (Fig EV1G and H).
To investigate whether erlotinib showed effective penetration
into OSs, 6-month-old H2-c-fosLTR/Egfrwt mice with OS, as
confirmed with Na[18F]F PET imaging, underwent PET scans after
i.v. injection of [11C]erlotinib at a dose of 2 mg/kg, which corre-
sponds to a human therapeutic dose. Previous results indicated
negligible metabolism of [11C]erlotinib in mice over the duration of
a PET scan, so that radioactivity signal in OSs of H2-c-fosLTR/Egfrwt
mice can be expected to be only composed of unmetabolized
[11C]erlotinib, thereby allowing for quantification of erlotinib concen-
trations in tumor tissue (Traxl et al, 2015). PET images revealed that
erlotinib penetrated into OSs, while it was excluded from the brain
as a pharmacological sanctuary site due to efflux transport at the
blood–brain barrier (Fig 1I). Maximum erlotinib concentrations in
OSs of individual animals ranged from 3.9 to 10.2 lM, which is in a
similar range as peak plasma concentrations of erlotinib achieved in
cancer patients after oral dosing (Fig 1J; Katsuya et al, 2015).
EGFR in osteoblasts promotes OS formation in
H2-c-fosLTR mice
Next, we analyzed the cell type in which EGFR is required to induce
OS formation, as we and others have recently shown that EGFR
expression in myeloid cells is essential for the development of hepa-
tocellular and colorectal cancer (Lanaya et al, 2014; Hardbower
et al, 2017; Srivatsa et al, 2017). We employed the myeloid-specific
LysM-Cre line and the osteoblast-specific Runx2-Cre line to condi-
tionally delete EGFR in myeloid cells or osteoblasts of H2-c-fosLTR
mice, respectively. EGFR deletion in myeloid cells did not affect OS
development in terms of differences in tumor number, burden or
serum ALP levels, suggesting that EGFR expression in myeloid cells,
which include bone-resorbing osteoclasts, is dispensable during
c-Fos-induced OS formation (Appendix Fig S1A–C).
In contrast, deletion of EGFR in the osteoblastic lineage (EgfrDOb)
led to significantly reduced tumor number, size, and lower serum
ALP levels, demonstrating that EGFR expression in osteoblasts is
essential for OS formation (Fig 2A–D). Imaging by lPET/CT with
the PET tracer Na[18F]F, which is both oncotropic and osteotropic,
provides a functional readout on osteoblastic cell activity and tumor
burden (Broadhead et al, 2015; Rohren et al, 2015). This analysis
revealed that H2-c-fosLTR/EgfrDOb mice showed significantly
reduced standardized uptake values (SUV) of Na[18F]F in pelvic OSs
at 4 and 7 months of age (Fig 2E and F) emphasizing the require-
ment for EGFR in osteoblasts for OS development.
EGFR deletion in osteoblasts decreases proliferation and survival
with reduced pRSK2/pCREB/c-Fos activation
As Egfr deletion in the osteoblastic lineage affects normal bone
development (Linder et al, 2018), we next investigated whether
EGFR deletion also induces histomorphological changes in c-Fos-
dependent OS. Bone volume analysis confirmed that osteoblast-
specific deletion of EGFR does not affect the mineralization capacity
of OSs (Fig EV2A). Tartrate-resistant acid phosphatase (TRAP)
staining further revealed that EGFR is dispensable for osteoclastoge-
nesis in H2-c-fosLTR-derived bone tumors (Fig EV2B). Moreover,
expression levels of osteoblast-specific differentiation markers were
not significantly changed in H2-c-fosLTR/EgfrDOb tumors, indicating
that EGFR expression from osteoblastic cells does not affect osteo-
blast cellularity or differentiation in OSs (Fig EV2C and D).
We next assessed the molecular mechanisms by which osteo-
blast-specific EGFR deletion impairs OS development. In line with
results from the lPET/CT analysis (Fig 2E and F), H2-c-fosLTR/
EgfrDOb-derived OSs exhibit significantly reduced proliferation and
survival compared to H2-c-fosLTR/Egfrwt mice, as shown by
decreased PCNA and elevated cleaved caspase-3 IHC staining
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(Fig 3A). In line, OSs from H2-c-fosLTR/EgfrDOb mice also displayed
decreased expression of cyclin D1 mRNA (Fig 3B) and protein
(Fig EV2E). Interestingly, OSs from H2-c-fosLTR/EgfrDOb mice had
significantly reduced mRNA expression levels of c-fos, while trans-
genic c-fos (c-fostg) was unaffected indicating that EGFR controls
endogenous c-fos expression (Fig 3B). Osteoblast-specific EGFR
deletion also led to reduced pRSK2, decreased pCREB and less c-
Fos-positive cells in OS, as shown by IHC (Fig 3C) and Western blot
analysis of bone tumors from 6- to 7-month-old mice (Fig EV2F).
Moreover, EGFR deletion also significantly reduced RSK2-mediated
phosphorylation of c-Fos at Ser362 (Fig EV2G). These data indicate
that EGFR signaling in osteoblasts is not only essential for prolifera-
tion and survival, but also controls endogenous c-fos expression and
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EGFR activates pCREB/c-Fos via MAPK
To further demonstrate the cell-autonomous requirement for EGFR/
pRSK2/pCREB/c-Fos activation in osteoblasts, we next analyzed OS
cells isolated from H2-c-fosLTR/EgfrDOb and H2-c-fosLTR/Egfrwt
mice. In line with our in vivo findings, we detected strongly reduced
protein levels of pCREB and c-Fos in H2-c-fosLTR/EgfrDOb OS cells
(Fig 4A) and significantly reduced expression of c-fos mRNA, while
levels of the transgenic c-fos (c-fostg) in OS cells lacking EGFR
were comparable to Egfrwt OS cells (Fig 4B). H2-c-fosLTR/EgfrDOb
OS cells also showed significantly increased apoptosis and reduced
proliferation as evidenced by elevated levels of cleaved caspase-3
and cleaved PARP (Fig EV3A) and reduced Ki-67-positive cells
(Fig EV3B) when compared to H2-c-fosLTR/Egfrwt OS cells.
Moreover, EGFR inhibition with erlotinib resulted in a dose-
dependent downregulation of pRSK2/pCREB/c-Fos in H2-c-fosLTR/
Egfrwt OS cells (Fig 4C) leading to reduced proliferation as shown
by reduced cyclin D1 protein levels (Fig EV3C) and less Ki-67-posi-
tive cells (Fig EV3D). Erlotinib treatment also led to significantly
reduced c-fos mRNA expression without affecting transgenic c-fos
mRNA levels, further demonstrating that EGFR signaling specifically
promotes transcription of endogenous c-fos (Fig 4D).
◀ Figure 1. EGFR signaling is essential for c-Fos-dependent bone tumor formation.A X-ray analysis of 6-month-old H2-c-fosLTR/Egfrwa/+ and H2-c-fosLTR/Egfrwa/wa littermates. Scale bars: 1 cm.
B Bone tumor number per mouse at 5–6 months of age (n = 23 wa/+, 15 wa/wa).
C Quantification of tumor size in tibiae at 5–6 months of age (n = 23 wa/+, 15 wa/wa).
D Alkaline phosphatase (ALP) levels in the serum at endpoint (age = 5–6 months; n = 16 wa/+, 11 wa/wa).
E X-ray analysis before (age = 2 months) and after (age = 7 months) vehicle or erlotinib treatment. Scale bars: 1 cm.
F Quantification of tumor number during treatment (n = 6 vehicle, 5 erlotinib).
G Tumor size during treatment (n = 6 vehicle, 5 erlotinib).
H Analysis of serum ALP levels during treatment (n = 5).
I PET summation images (0–90 min) in horizontal (upper panel) and coronal view (lower panel) depicting [11C]erlotinib distribution in one H2-c-fosLTR/Egfrwt mouse
(M125). Anatomical structures are labeled with arrows (T, tumor; L, liver; H, heart; B, brain). Scale bars: 1 cm.
J Concentration–time curves of [11C]erlotinib in bone tumors in right scapula of three H2-c-fosLTR/Egfrwt mice measured with PET. Broken line indicates threshold for
in vitro effect of erlotinib (1 lM).































































































Figure 2. Osteoblast-specific EGFR deletion reduces c-Fos-driven OS formation.
A X-ray analysis of 7-month-old H2-c-fosLTR/Egfrwt and H2-c-fosLTR/EgfrDOb littermates. Scale bars: 1 cm.
B Bone tumor number per mouse at 6–7 months of age (n = 22 wt, 11 DOb).
C Quantification of tumor size in tibiae (n = 22 wt, 11 DOb).
D ALP levels in the serum at 7-month endpoint (n = 17 wt, 8 DOb).
E lPET/CT analysis of 7-month-old H2-c-fosLTR/Egfrwt and H2-c-fosLTR/EgfrDOb littermates.
F Standardized uptake values (SUV) of the lPET tracer Na[18F]F in the pelvic OS of 4- and 7-month-old H2-c-fosLTR/Egfrwt and H2-c-fosLTR/EgfrDOb mice. n = 6 wt,
4 DOb for 4-month time-point, n = 6 wt, 3 DOb for 7-month time-point.
Data information: Data are shown as mean  SEM. P-values were calculated by unpaired, two-tailed t-test.
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We next dissected the molecular signaling pathway downstream
of EGFR responsible for activation of pCREB and c-Fos. Because
RSK2 activation depends on ERK1/2 and PI3K-dependent PDK-1
signaling (Anjum & Blenis, 2008), serum-starved H2-c-fosLTR/
Egfrwt OS cells were pre-treated with inhibitors against EGFR (afa-
tinib), PDK1 (GSK2334470), mTOR (rapamycin), or ERK1/2
(U0126) and afterwards stimulated with EGF (50 ng/ml) for 0, 5,
or 30 min (Fig 4E and F). As expected, EGF strongly induced
RSK2/CREB phosphorylation after 5 min followed by elevated
c-Fos protein levels after 30 min of stimulation (Fig 4E). Compara-
ble expression patterns were also detected in cells pre-treated with
a PDK-1 or mTOR inhibitor, suggesting that the PI3K pathway is
dispensable for pCREB/c-Fos activation (Fig 4E). Importantly,
when ERK1/2 was blocked, upregulation of the two target proteins
was not detected (Fig 4E), indicating that EGF-induced activation
of pCREB/c-Fos in c-fos transgenic OS cells depends on MAPK
signaling.
To further demonstrate that EGFR signaling is mainly affecting
the expression of endogenous but not transgenic c-fos, primary OS
cells isolated from p53f/f Rb1f/f Osx-Cre mice were employed. It has
been reported, that c-fos is upregulated in primary OS cells isolated
from these mice (Walkley et al, 2008). In agreement with the results
obtained with primary H2-c-fosLTR OS cells, also p53f/f Rb1f/f Osx-
Cre OS cells showed reduced pRSK2/pCREB/Fos protein levels
(Fig 4G) and significantly downregulated c-fos mRNA expression
after erlotinib treatment (Fig 4H). On the other hand, strong activa-
tion of pEGFR/pRSK2/pCREB/c-Fos was induced after EGF stimula-
tion (Fig 4I). These data indicate that the observed mechanism of
EGFR-dependent activation of c-Fos via pRSK2/pCREB also applies
for bone tumors that are not induced by transgenic c-fos.
Osteoblast-specific overexpression of the EGFR ligand AREG
accelerates OS formation
Next, we wanted to investigate whether constitutive activation of
the EGFR pathway can enhance bone tumor formation. We there-
fore bred H2-c-fosLTR mice to mice overexpressing the EGFR ligand
Amphiregulin (AREG) under the control of the osteoblast-specific
col1a1 promoter (ColAREG) (Vaidya et al, 2015). Double transgenic
mice (H2-c-fosLTR/ColAREG) showed significantly increased tumor
numbers, size and a tendency of elevated serum ALP levels
(Fig 5A–D), indicating that autocrine osteoblast-specific EGFR acti-
vation accelerates OS development.
Tumors from double transgenic mice displayed significantly
increased AREG protein (Appendix Fig S2A) and mRNA expression
levels (Appendix Fig S2B) and elevated EGFR phosphorylation
(Appendix Fig S2C). Moreover, they showed significantly increased
c-fos mRNA expression levels (Fig 5E), whereas the transgenic c-fos
mRNA in the tumor was not significantly changed (Appendix Fig
S2D). Western blot analysis further revealed that bone tumors of H2-
c-fosLTR/ColAREG mice displayed elevated activation of the EGFR
downstream proteins pRSK2, pCREB and c-Fos resulting in elevated
proliferation with increased cyclin D1 protein expression (Fig 5F)
and decreased apoptosis as shown by reduced cleaved caspase-3
levels (Fig 5G). These data demonstrate that constitutive AREG-
induced EGFR activation accelerates tumorigenesis in H2-c-fosLTR
A




































































































































Figure 3. EGFR is essential for proliferation, survival and c-Fos protein and mRNA expression via RSK2/CREB phosphorylation.
A PCNA and cleaved caspase-3 IHC staining and quantification shown as % positive cells (for PCNA) and as positive cells per mm2 (for cleaved caspase-3) in OS from
H2-c-fosLTR/Egfrwt (n = 6) and H2-c-fosLTR/EgfrDOb (n = 5) mice. Scale bars: 100 lm.
B Egfr, Ccnd1, c-fos and transgenic c-fos (c-fostg) mRNA expression levels in tumors of H2-c-fosLTR/Egfrwt and H2-c-fosLTR/EgfrDOb mice normalized to Tbp. n = 17 wt, 14
DOb (Egfr, Ccnd1), n = 16 wt, 13 DOb (c-fos), n = 16 wt, 14 DOb (c-fostg).
C IHC staining and quantification showing pRSK2- (n = 4), pCREB- (n = 7 wt, 6 DOb), and c-Fos (n = 5)-positive cells (%) in OS from H2-c-fosLTR/Egfrwt and H2-c-fosLTR/
EgfrDOb littermates. Scale bars: 100 lm.
Data information: Data are shown as mean  SEM. P-values were calculated by unpaired, two-tailed t-test.
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mice via enhanced tumor cell proliferation and survival resulting
from increased pRSK2/pCREB/c-Fos signaling.
EGFR and c-Fos co-expression correlates with poor survival of
human OS patients
To investigate whether our findings in the FOS-driven OS mouse
model are of clinical relevance, we stained biopsies from 52
human OS patients with antibodies directed against EGFR and c-
Fos and divided them, according to their expression levels, into
two groups (positive or negative; Fig 6A). In line with published
studies (Do et al, 2009; Lee et al, 2012), we did not find any
significant correlation between EGFR expression and overall
survival of OS patients (Fig EV4A). Also c-Fos expression in bone
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Figure 4. EGFR controls c-Fos via MAPK-dependent CREB activation in primary OS cells.
A Western blot analysis of primary OS cells isolated from H2-c-fosLTR/Egfrwt and H2-c-fosLTR/EgfrDOb mice.
B c-fos and transgenic c-fos (c fostg) mRNA expression levels in primary H2-c-fosLTR OS cells after 4× in vitro passages, cultured under standard conditions (n = 3
independent cell lines).
C Western blot analysis of H2-c-fosLTR/Egfrwt OS cells treated for 24 h with erlotinib.
D c-fos and c-fostg mRNA expression levels in H2-c-fosLTR/Egfrwt OS cells treated for 24 h with erlotinib (10 lM) or DMSO as control (n = 4 independent cell lines).
E, F Western blot analysis of starved H2-c-fosLTR/Egfrwt OS cells, pre-treated with DMSO (1:1,000), afatinib (5 lM), GSK2233470 (10 lM), rapamycin (10 nM), or U0126
(10 lM) for 30 min and stimulated with EGF (50 ng/ml) as indicated.
G Western blot analysis of primary OS cells isolated from a p53f/f Rb1f/f Osx-Cre mouse after 24-h erlotinib treatment.
H c-fos mRNA expression levels in p53f/f Rb1f/f Osx-Cre OS cells treated for 24 h with erlotinib (10 lM; n = 3).
I Western blot analysis of starved p53f/f Rb1f/f Osx-Cre OS cells, pre-treated with DMSO (1:1,000) or afatinib (5 lM) for 30 min and stimulated with EGF (50 ng/ml) as
indicated.
Data information: Data are shown as mean  SEM. P-values were calculated by unpaired, two-tailed t-test.
Source data are available online for this figure.
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However, when we stratified patients according to the co-expres-
sion of EGFR and c-Fos we found significantly reduced survival of
patients with tumors that showed high levels of both proteins
(Fig 6B), suggesting that EGFR inhibition might be a possible treat-
ment option for patients suffering from EGFR and FOS double-
positive OS.
Analysis of RNAseq data of human OS from a publicly available
dataset [GSE39058 (Kelly et al, 2013)] further revealed that EGFR
expression significantly correlated with FOS expression (Fig 6C). In
contrast, except for PDGFRB, other cancer-associated receptor tyro-
sine kinases (RTKs) showed either negative or no correlation with
FOS expression (Fig 6C). However, applying linear models for
microarray and RNAseq data (LIMMA) analysis revealed that
human OS high for both EGFR and FOS did not show any signifi-
cantly changed transcriptional profile as compared to double-nega-
tive OS (Dataset EV1). Among EGFR ligands, only TGFa showed a
significant correlation with FOS expression, indicating that TGFa
might be crucial for EGFR activation in FOS-dependent OSs
(Fig EV4C).
EGFR signaling in human OS cell lines and orthotopic tumors
We next tested our hypothesis that EGFR inhibition is more effective
in OSs positive for both EGFR and c-Fos, and analyzed their
expression levels in a panel of human OS cell lines. Among six
tested cell lines, only the highly aggressive 143b cells showed co-
expression of both EGFR and c-Fos protein and mRNA, whereas
LM7 cells expressed only detectable levels of EGFR but not of c-Fos
(Figs 7A and EV5A). Moreover, EGF stimulation of starved LM7
cells did not induce c-Fos protein expression, excluding the possibil-
ity that c-Fos gets activated via EGFR signaling in this cell line
(Fig EV5B).
In line with our hypothesis, in vitro erlotinib treatment signifi-
cantly reduced the cell viability in 143b cells, but not in LM7 cells
(Fig 7B). Conversely, EGF stimulation led to elevated cell viability
only in 143b, but not in LM7 cells (Fig 7C), indicating that OS cells
become addicted to EGFR signaling only if they express both EGFR
and c-Fos. To demonstrate that c-Fos is essential in 143b OS cells, we
knocked down c-fos in these cells by employing doxycycline-inducible
shRNA (Fig EV5C and D) to show that both cell proliferation and cell
viability were reduced in 143b OS cells lacking c-fos (Fig EV5E–H).
An orthotopic OS model mimicking the human disease was
employed to investigate whether our findings also hold true in vivo.
For this purpose, the human OS cell lines 143b and LM7 were injected
into the proximal marrow space of the tibia bone of immunosup-
pressed mice. After tumors had developed, mice were divided into
groups with equal mean tumor volumes and treated with erlotinib





Figure 5. Osteoblast-specific overexpression of the EGFR ligand Amphiregulin accelerates tumor formation in H2-c-fosLTR mice.
A X-ray analysis of 6-month-old H2-c-fosLTR and H2-c-fosLTR/ColAREG littermates. Scale bars: 1 cm.
B Bone tumor number per mouse at 5–6 months of age (n = 22 wt, 13 ColAREG ).
C Quantification of tumor size in tibiae at 5–6 months of age (n = 22 wt, 13 ColAREG ).
D Alkaline phosphatase (ALP) levels in the serum at endpoint (age = 5–6 months; n = 29 wt, 19 ColAREG ).
E c-fos mRNA expression levels in OSs of H2-c-fosLTR (n = 11) and H2-c-fosLTR/ColAREG mice (n = 14).
F, G Western blot analysis of bone tumor protein lysates from H2-c-fosLTR and H2-c-fosLTR/ColAREG mice.
Data information: Data are shown as mean  SEM. P-values were calculated by unpaired, two-tailed t-test.
Source data are available online for this figure.
ª 2018 The Authors EMBO Molecular Medicine 10: e9408 | 2018 7 of 15
Markus Linder et al EGFR promotes osteosarcoma development EMBO Molecular Medicine
Published online: October 25, 2018 
Similar to what was observed in vitro, 143b-derived xenografts
showed high EGFR and c-Fos protein expression, whereas LM7-
induced tumors only expressed EGFR (Fig EV5I) but no c-Fos
(Fig EV5J). Importantly and in agreement with patient survival data
(Fig 6B), xenografts from EGFR and c-Fos double-positive 143b cells
were more aggressive, resulting in significantly shorter median
survival and twofold to threefold increased tumor progression as
compared to LM7-derived tumors (Yuan et al, 2009; Ren et al,
2015b). Erlotinib treatment strongly reduced EGFR phosphorylation
in both xenograft models (Fig EV5K). Erlotinib-induced tumor reduc-
tion at the endpoint was exclusively detectable in 143b-derived OS,
whereas LM7-derived OS did not show any significant differences in
tumor size or weight after erlotinib therapy (Fig 7D–I). The results
from this preclinical trial demonstrate that EGFR inhibition only
reduces OS progression in tumors that co-express both EGFR and c-
Fos (Fig 7E and F) confirming EGFR as a driver in this subclass of OS.
We next assessed whether in the 143b OS xenograft model EGFR
inhibition also affected proliferation and survival via pCREB/c-Fos
as seen in H2-c-fosLTR mice. IHC stainings revealed significantly
reduced levels of PCNA and increased numbers of cleaved caspase-3-
positive cells in tumors after erlotinib treatment (Fig 7J). This,
together with reduced protein levels of Ki-67 and cyclin D1
(Fig EV5L and M), indicates that EGFR plays an essential role during
proliferation and apoptosis in orthotopically injected 143b OS cells.
Additionally, we found significantly reduced pCREB/c-Fos levels in
143b-derived tumors after erlotinib treatment as shown by IHC
(Fig 7K) and Western blot analysis (Fig 7L). In summary, these data
provide strong evidence that EGFR-dependent activation of pCREB/
c-Fos represents a driving pathway in EGFR/Fos double-positive OS.
Discussion
EGFR inhibition in human OS cell lines has been shown to effec-
tively decrease cell migration, cell invasion and colony formation
(Messerschmitt et al, 2008). Other studies suggested that EGFR inhi-
bition has no significant influence on cell proliferation, but
enhances the anti-tumor effects of starvation or chemotherapy-
induced cell stress in vitro (Sevelda et al, 2015). Our study shows
that EGFR is a driver of OS, at least in a subgroup of patients suf-
fering from EGFR and c-Fos double-positive tumors.
We found significantly reduced OS formation in H2-c-fosLTR
mice, when we either genetically deleted EGFR or pharmacologically
inhibited the receptor. Moreover, cell-type-specific EGFR knock-out
models revealed that EGFR signaling in osteoblasts is the driving
force essential for c-Fos-dependent OS formation, whereas myeloid-
cell-specific deletion of EGFR did not affect osteosarcomagenesis.
This is in contrast to our previous findings in colorectal and hepato-
cellular carcinoma, where EGFR expression in myeloid cells was
found to be essential for tumor formation (Lanaya et al, 2014;
Srivatsa et al, 2017), indicating that the tumorigenic role of EGFR
varies depending on the tumor and cell type.
As bone tumors in H2-c-fosLTR mice arise from the osteoblastic
lineage (Grigoriadis et al, 1993), we hypothesize that the tumor cell-
intrinsic function of EGFR might be similar to its role in pancreatic
ductal adenocarcinoma (PDAC), where EGFR deletion or inhibition
was shown to ameliorate KRAS-driven PDAC (Ardito et al, 2012;
Navas et al, 2012). It would be of interest to address whether the
molecular mechanisms in c-Fos-dependent OSs also hold true for
KRAS-mutated PDACs in which c-Fos was also reported to be a
major driver (Guo et al, 2015; You et al, 2016).
Clinical studies have linked expression of the EGFR ligand AREG
to poor prognosis of patients suffering from carcinomas such as
pancreatic, breast, or colorectal cancer (Willmarth & Ethier, 2008;
Yamada et al, 2008; Wang et al, 2016). A recent study by Liu et al
(2015) concluded that AREG also promotes cell migration and meta-
static capacity of human OS cells as shRNA-mediated knock-down
of AREG resulted in significantly less lung metastasis nodules after
i.v. injection. In line with this study, we found significantly elevated
tumor formation and progression when we boosted EGFR signaling


























































Figure 6. EGFR and c-Fos co-expression in human OS negatively correlates with patient survival.
A Representative images of OS biopsies stained with antibodies against EGFR and c-Fos. Scale bars: 50 lm.
B Kaplan–Meier survival curve comparing the survival of patients with EGFR and c-Fos double-positive OSs against patients without co-expression of both proteins
(n = 52).
C Gene expression correlation analysis of several cancer-associated RTKs with FOS in human OS (data analyzed from publicly available dataset E-GEOD-39058).
Data information: P-values were calculated by log-rank (Mantel–Cox) test comparing the two Kaplan–Meier curves (B) or by unpaired, two-tailed t-test (C).
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Figure 7. EGFR inhibition decreases tumor progression of human OS cells 143b after orthotopic injection.
A Western blot analysis showing EGFR and c-Fos protein levels in human OS cell lines cultured under standard conditions.
B Cell viability of 143b or LM7 cells cultured for 24 h in medium (+10% FCS) with DMSO (1:2,000) or erlotinib (10 lM; n = 3, representative result from three
independent experiments, shown as fold change, normalized to DMSO).
C Cell viability of 143b or LM7 cells cultured for 24 h in medium (+0.5% FCS) containing 1× PBS (contr., 1:200) or EGF (50 ng/ml; n = 3, representative result from three
independent experiments, shown as fold change, normalized to control).
D Treatment scheme: 143b OS cells (106 in 25 ll PBS) were intratibially injected; mice were treated for 14 days with vehicle or erlotinib (50 mg/kg) 7 days after
injection, when the tumors started to grow.
E 143b xenograft growth curve during therapeutic regime (n = 8 vehicle, 6 erlotinib; two independent experiments).
F 143b tumor weight at endpoint (n = 8 vehicle, 6 erlotinib; two independent experiments).
G Treatment scheme: LM7 OS cells (106 in 25 ll PBS) were intratibially injected; mice were treated for 21 days with vehicle or erlotinib (50 mg/kg) 42 days after
injection, when the tumors started to grow.
H LM7 xenograft growth curve during therapeutic regime (n = 7 vehicle, 5 erlotinib; two independent experiments).
I LM7 tumor weight at endpoint (n = 7 vehicle, 5 erlotinib, two independent experiments).
J IHC analysis of PCNA and cleaved caspase-3 in 143b-derived tumors (n = 4). Scale bars: 50 lm.
K IHC analysis of pCREB and c-Fos in 143b-derived tumors (n = 5 for pCREB and n = 4 for c-Fos analysis). Scale bars: 50 lm.
L Western blot analysis of pCREB/CREB and p-c-Fos/c-Fos protein expression in lysates directly isolated from 143b xenografts at endpoint, after 14 days of vehicle or
erlotinib treatment.
Data information: Data are shown as mean  SEM. P-values were calculated by unpaired, two-tailed t-test (B, C, F, I, J, and K) or by two-way ANOVA followed by
Bonferroni multiple comparison test (E and H).
Source data are available online for this figure.
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in bone tumors by crossing H2-c-fosLTR mice to mice that overex-
press AREG under an osteoblast-specific promoter (ColAREG),
suggesting that AREG could indeed be a clinically relevant molecule
in OS development.
Mechanistically, we found that EGFR is essential for prolifera-
tion, survival, and MAPK-dependent activation of pCREB/c-Fos in
bone tumors of H2-c-fosLTR mice and in orthotopically injected
human 143b OS cells, which are positive for both EGFR and Fos. As
it has been reported that the MAPK-signaling protein RSK2 is essen-
tial for progression of OSs in H2-c-fosLTR mice (David et al, 2005),
it is likely that EGFR acts as the upstream receptor controlling RSK2
phosphorylation, which in turn activates and stabilizes the c-Fos
protein leading to OS progression. In addition, it has been shown
that endogenous c-fos expression levels directly correlate with tumor
formation in H2-c-fosLTR mice (Wang et al, 1995). Mice heterozy-
gous for c-fos (c-fos+/) developed about 50% less OSs, whereas
c-fos full knock-out mice (c-fos/) were nearly tumor-free (Wang
et al, 1995). In this study, we discovered that EGFR signaling is
essential for endogenous c-fos mRNA expression. Interestingly,
RSK2 deletion was shown not to affect endogenous c-fos transcrip-
tion in bone tumors of H2-c-fosLTR mice (David et al, 2005). There-
fore, we speculate that EGFR controls c-fos transcription directly via
ERK1/2, which has indeed been shown to induce c-fos mRNA
expression after binding to RSK2-independent phosphorylation sites
on the carboxyl-terminal transactivation domain (Monje et al,
2003). While we can distinguish transgenic c-fos mRNA from total
c-fos mRNA, we cannot distinguish the c-Fos protein expressed from
the transgene. Therefore, we can formally not rule out the possibil-
ity that EGFR also affects transgenic c-Fos protein levels. To con-
firm that EGFR mainly plays a role in endogenous c-Fos activation,
we used an independent preclinical OS model, which is based on
osteoblast-specific deletion of the two tumor suppressor genes p53
and Rb1 (Walkley et al, 2008). Also in this model, c-fos is upregu-
lated in p53f/f Rb1f/f Osx-Cre OS cells suggesting a potential
tumorigenic role for c-Fos in this model (Walkley et al, 2008). We
found that c-fos mRNA and pRSK2/pCREB/c-Fos protein levels
were significantly reduced after EGFR inhibition, demonstrating
that the here proposed mechanism does likely not depend on the
c-fos transgene.
By analyzing biopsies from human OS patients, we could not
detect any significant impact of EGFR expression on overall patient
survival, which is similar to previous reports (Do et al, 2009; Lee
et al, 2012). However, histological analysis of OS patients by Wen
et al (2007) revealed high EGFR expression in 4 out of 5 (80%)
recurring lesions, whereas only 14 out of 37 (38%) primary tumors
showed such high EGFR protein levels. Surprisingly, one study
reported a positive correlation between EGFR expression and good
clinical outcome in high-grade OS patients, which might be due to
the fact that patients with high EGFR levels show better responses
to conventional therapies (Kersting et al, 2007). In contrast, another
recent report found a significant correlation between high EGFR
levels in OS and reduced patient survival (Wang et al, 2018). Since
OS is a rare tumor, the few numbers of OS patients preclude a
comprehensive investigation. Thus, the potential of anti-EGFR
agents in the treatment of human OS remained elusive, raising the
need to identify prognostic molecular markers for future treatment
approaches. When we categorized OS patients according to the co-
expression of both proteins, EGFR and c-Fos, we found significantly
reduced overall survival within this sub-population. Thus, staining
OS patient biopsies for these two biomarkers could be a valuable
approach to predict disease progression. Although c-Fos could be
downstream of many other RTKs expressed in OS, RNAseq analysis
revealed that besides EGFR, only PDGFRB significantly correlated
with FOS expression indicating that PDGFRb signaling might also
act as an upstream activator for c-Fos-dependent OS. Previous
reports have shown that PDGFR is indeed frequently overexpressed
in OS and preclinical studies further suggested a tumor-promoting
role for PDGFR (McGary et al, 2002; Kubo et al, 2008).
In future, EGFR and c-Fos could be useful biomarkers to stratify
OS patients. A previous report showed that c-fos expression changed
in human squamous cell carcinomas after EGFR-TKI treatment and
correlated with therapy response in xenograft models (Jimeno et al,
2006). However, the potential use of FOS for predicting therapy
response was not demonstrated. In the current study, we show that
only OSs which express c-Fos respond to anti-EGFR treatment,
thereby identifying FOS as a potent predictive biomarker in OS
patients. We found that orthotopic bone tumors induced with the
EGFR and c-Fos expressing 143b OS cell line were responsive to
anti-EGFR treatment, whereas LM7 cells, which only express EGFR
but not c-Fos, did not respond to erlotinib. A recent study also
reported that treatment with cetuximab, a clinically used anti-EGFR
antibody, led to significantly reduced tumor formation after intratib-
ial injection of 143b cells (Gvozdenovic et al, 2017). Taken together,
our results indicate that anti-EGFR therapies will be successful in
patients with FOS-positive OS, where EGFR seems to be a tumor
driver. These results might allow better OS patient stratification and
therefore offer new therapeutic approaches for a rare tumor type for
which there are basically no treatment options.
Materials and Methods
Mice
Egfrf/f (Natarajan et al, 2007), Egfrwa2/wa2 (Luetteke et al, 1994),
Runx2-Cre (Rauch et al, 2010), LysM-Cre (Clausen et al, 1999), H2-
c-fosLTR (Ruther et al, 1989), and ColAREG (Vaidya et al, 2015)
mice have been described previously. Egfrf/f, H2-c-fosLTR, Runx2-
Cre, and LysM-Cre mice were maintained on a pure C57/BL6J back-
ground. Egfrwa2/wa2 and ColAREG mice were maintained on a mixed
genetic background. Both males and females were used indiscrimi-
nately. Mice were analyzed between 2 and 7 months of age as indi-
cated in the corresponding figure legend. The animals were
monitored and analyzed without randomization or blinding. Mice
were kept in the animal facility of the Medical University of Vienna
with unlimited access to both water and standard laboratory chow
under a light–dark cycle of 12 h at 22°C in accordance with institu-
tional policies and federal guidelines. All animal experiments
conducted were compliant with federal laws and guidelines of the
Medical University of Vienna.
Cell culture
Human OS cell lines U2OS, SaOS2, HOS, 143b, and MG63 were
purchased from ATCC (Manassas, VA). The LM-7 OS cell line (Jia
et al, 1999) was provided by Dr. Eugenie S. Kleinerman from the
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M.D. Anderson Cancer Center (University of Texas). 143b OS cells
have been reported not to carry any EGFR mutations (Wen et al,
2007). 143b cells were cultured in DMEM supplemented with 10%
FCS (Sigma), and LM7 cells were cultured in MEM with non-essen-
tial amino acids, pyruvate, and 10% FCS (Sigma). Primary mouse
OS cells were isolated and cultured as previously described (Grigori-
adis et al, 1993). For EGFR inhibitor experiments, sub-confluent
cells were treated with indicated concentrations of erlotinib (Santa
Cruz Biotechnology) for 24 h in normal growth medium (DMEM
+10% FCS; Sigma). For in vitro stimulation experiments, cells were
serum-starved overnight and pre-treated for 30 min with DMSO
(1:1,000) or inhibitors against EGFR (5 lM afatinib, Santa Cruz
Biotechnology), PDK-1 (10 lM GSK2334470, Selleckchem), mTor
(10 nM rapamycin, Sigma), or ERK1/2 (10 lM U0126, Cell Signaling
Technology). Afterward, cells were stimulated for 0, 5, or 30 min
with 50 ng/ml recombinant EGF (PeproTech). All cell lines were
tested and showed no mycoplasma contamination.
Gene silencing using shRNA
To knock down (KD) FOS, HEK 293T cells were transduced with
lentiviral FOS shRNA expression vectors (Tet-pLKO-neo-FOS) with
pCMV-D89 plasmid and pVSV-G envelop plasmid, and then
lentiviral particles from culture supernatants were used to infect
143b cells, which were selected with Neomycin (500 lg/ml) for
1 week.
shRNA oligo primer sequences for FOS were as follows: Fw: CCG
GTC TGC TTT GCA GAC CGA GAT TCT CGA GAA TCT CGG TCT
GCA AAG CAG ATT TTT G and Rv: AAT TCA AAA ATC TGC TTT
GCAGAC CGAGAT TCT CGAGAA TCT CGG TCT GCAAAGCAGA.
Immunofluorescence staining
For in vitro immunofluorescence (IF) staining, cells were seeded on
chamber slides (2-well or 8-well) and cultured/treated as indicated
in the figure legends. After removing the medium, cells were
washed with PBS and fixed with 4% PFA for 20 min at room
temperature. The fixed cells were washed and permeabilized with
0.1% Triton X-100 in PBS for 10 min at room temperature. After-
ward, cells were washed and blocked with 2% BSA and 5% normal
goat serum in PBS for 1 h at room temperature. Antibodies (see
Appendix Table S1) were incubated in blocking buffer overnight at
4°C. After washing with PBS, 100 ll of secondary antibody (donkey
anti-rabbit Alexa Fluor 555) diluted 1:500 in blocking buffer was
added and incubated for an hour at room temperature. After wash-
ing with PBS, the slide was mounted with aqueous mounting
medium and observed using a fluorescent microscope.
MTT assay
Cells were seeded at a density of 500 cells/well in 96-well plates and
cultured for 48, 96, and 144 h with/without doxycycline (500ng/ml),
respectively. Subsequently, 25 ll of MTT reagent (5 mg/ml) was
added to each well and incubated for 2 h at 37°C. After removing
media, wells were washed with PBS and then the remaining crystals
were dissolved in dimethyl sulfoxide. The absorbance was evaluated
at 570 nm (background is 630 nm). The assays were performed in
triplicate.
Cell viability assay
For cell viability assay, cells (1.5 × 103/cm2 for LM7; 1.5 × 102/cm2
for 143b) were seeded in white, opaque-walled 96-well plates
(Thermo Fisher). After 24 h, cells were treated with DMSO
(1:2,000) or erlotinib (10 lM) in normal growth medium containing
10% FCS or stimulated with EGF (50 ng/ml) in growth medium
containing 0.5% FCS. After 24 h of treatment/stimulation, cell
viability was measured using the CellTiter-Glo Luminescent Cell
Viability Assay Kit (Promega) according to manufacturer’s
instructions.
In vivo imaging
For X-ray analysis, mice were anesthetized and imaging was
performed using a Mobilett XP mobile X-ray machine (Siemens).
Tumor number was quantified from X-ray images using Photoshop
CS6 (Adobe), and tumor size was measured with ImageJ 1.49v
(Wayne Rasband, NIH, USA).
Imaging experiments were conducted with a small animal
computed tomography (CT) and positron emission tomography
(PET) scanner (Siemens InveonTM multimodal lSPECT/PET/CT;
Siemens Preclinical Solutions, Knoxville, USA). Mice were anes-
thetized with 1.5–2% isoflurane mixed with oxygen (1.5 l/min) to
avoid movement during the imaging procedure. Subsequently, for
the PET image acquisition mice were administered fluorine-18
sodium fluoride (Na[18F]F) (21.09  3.86 MBq; 70  19 ll) via
retro-orbital injection. After an accumulation time of 60 min, a 10-
min static PET acquisition and a subsequent high-resolution whole-
body CT scan were performed. Vital parameters, such as respiration
and body temperature, were recorded continuously using a dedi-
cated physiological monitoring system (bioVet; m2mimaging, Cleve-
land, OH, USA).
CT raw data were reconstructed with a Feldkamp algorithm
using a Ramp filter followed by default beam-hardening correction.
PET data reconstruction was performed with an OSEM 3D/OP-MAP
algorithm with default parameters and attenuation corrected on the
basis of CT measurements. All data were normalized and corrected
for random, dead time, radioactive decay, and weight of the animal.
A calibration factor was applied to the data in order to convert the
units of the small animal PET images into absolute radioactivity
concentrations, expressed as standardized uptake values (SUV;
g/ml). PET and CT images were co-registered through an automati-
cally generated spatial transformation matrix. Biomedical image
analysis was accomplished using the Inveon Research Workplace
Software (IRW; Siemens Medical Solutions, Knoxville, TN, USA).
For image quantification, cylindrical volumes of interest were
drawn. The respective Na[18F]F uptake in the delineated areas was
expressed as SUV normalized to body weight.
PET experiments to study tissue distribution of [11C]erlotinib
were conducted at the Austrian Institute of Technology on a
microPET Focus 220 system (Siemens Medical Solutions) as
described in detail elsewhere (Traxl et al, 2017). In brief, 6-month-
old female H2-c-fosLTR/Egfrwt mice (n = 3) underwent under isoflu-
rane anesthesia 90-min dynamic PET scans after i.v. injection of a
mixture of [11C]erlotinib (47  12 MBq) and unlabeled erlotinib
hydrochloride (Apollo Scientific, Bredbury, UK) at a dose of 2
mg/kg. At the end of the [11C]erlotinib PET scan, animals received
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an i.v. injection of Na[18F]F (injected amount: 5  1 MBq) followed
by a 20-min static PET scan. PET data were reconstructed as des-
cribed (Traxl et al, 2017). Tumor volumes of interest were outlined
on the dynamic [11C]erlotinib PET images guided by the static Na
[18F]F PET images. Radioactivity concentration in tumors was
expressed in SUV units and multiplied by the administered erlotinib
dose of 2 mg/kg to obtain mass concentrations of erlotinib (lg/g).
Intratibial tumor cell injection and in vivo erlotinib treatment
For intratibial injection of tumor cells, 8- to 12-week-old female
nude mice were anesthetized and 143b or LM7 tumor cells (106 in
25 ll 1× PBS) were injected through the knee to the bone marrow
cavity of the left proximal tibia. Seven days (143b) or 6 weeks
(LM7) after injection, mice were randomized and treated for 14 days
(143b) or 21 days (LM7) with erlotinib (50 mg/kg bw, i.p.) or the
vehicle (0.5% Methylcellulose). Tumor volume was calculated by
caliper measurements of the injected tibia bone using the formula
Vol. = length × width2/2 minus the volume of the healthy, non-
injected leg as described elsewhere (Gvozdenovic et al, 2016). For
long-term treatment, 2-month-old male H2-c-fosLTR mice were
divided into two groups and treated with either erlotinib (25 mg/kg
bw, 5×/week, i.p.) or the vehicle (0.5% Methylcellulose, 5×/week,
i.p.; Politi et al, 2006). After 4 weeks of treatment, mice were left
untreated for 4 weeks until the treatment regime started again.
Tumor number and size as well as serum ALP levels were quantified
monthly.
Human mRNA expression data
For human mRNA expression data, the publicly available RNAseq
datasets E-GEOD-39058 (Kelly et al, 2013) were downloaded from
Gene Expression Omnibus and analyzed with the GEOquery pack-
age of R. The GSE39058 dataset also included recurrence-free
survival information. Expression data were stratified into EGFR/FOS
low and high expressers using the surv_cutpoint function of surv-
miner using recurrence-free survival as target variable. The gene
expression profile EGFR/FOS double low vs. double high was
analyzed using the LIMMA package of R.
Human OS tissue microarray
The human OS TMA was purchased from Novus Biologicals (Cata-
log Number: NBP2-30289). The TMA contained 4-lm-thick sections
of 59 bone cancer biopsies and one control biopsy from a non-
cancer patient. Seven patients had to be excluded from the analysis
due to: unknown cause of death (n = 2), died of heart disease
(n = 2), survival information not available (n = 2), and tissue lost
during IHC staining procedure (n = 1). The remaining 52 biopsies,
which were analyzed in the study, were derived from 39 male and
13 female patients with an average age of 20.2  11.2 years.
Immunohistochemistry
For immunohistological stainings, samples were fixed in 4% PBS-
buffered formalin, decalcified in 0.5 M EDTA (pH 8.0) and embedded
in paraffin. Immunohistochemistry was performed on 3-lm-thick
sections. Primary antibodies (for a full list, see Appendix Table S1)
were incubated overnight at 4°C followed by HRP-based immunore-
activity detection (Cell Signaling Technology). Non-specific binding
was blocked with TBS-T containing 2% BSA and 5% normal goat
serum. Quantification of IHC stainings was performed using the
ImageJ plugin ImmunoRatio (version: 1.0c, Jorma Isola and Vilppu
Tuominen, University of Tampere). For analysis of EGFR/c-Fos
expression in human OS, two consecutive sections from a commer-
cially available TMA (Novus, NBP2-30289) were stained with anti-
bodies directed against EGFR (Cell Signaling Technology, #4267) and
c-Fos (Santa Cruz Biotechnology, SC-52). For quantification, cores
were graded according to positive cells by two independent investi-
gators whereby more than 60% positive cells were considered as
positive/high. The results were afterward double-checked using an
automatized histology quantification program (Definiens Tissue
Studio 4.0).
RNA isolation, real-time qRT–PCR analysis
RNA isolation and qRT–PCR analysis were performed as described
previously (Linder et al, 2018). For a full list of primers used, see
Appendix Table S2.
Western blot analysis
Western blot analysis was performed as previously described
(Sibilia et al, 2000). For a full list of the antibodies used, please see
Appendix Table S1.
ELISA
Mouse Amphiregulin ELISA (Thermo Fisher) was performed accord-
ing to manufacturer’s instructions. Protein concentration was
analyzed using Bradford protein assay (Bio-Rad).
Analysis of alkaline phosphatase
Alkaline phosphatase serum levels were measured using diagnostic
ALP test stripes (Reflotron, Roche) and read on an automatic Reflo-
tron analyzer (Roche).
Statistical methods
Sample size of in vivo experiments was chosen based on previous
experience with similar studies in the laboratory. For analyses of
IHC and qRT–PCR data, univariable comparisons of expression
values between groups were analyzed by unpaired two-tailed
Student’s t-test with f-test to ensure comparable variances between
the groups. If the variances were significantly different, as measured
by f-test, unpaired two-tailed Student’s t-test with Welch’s correc-
tion was performed. For analysis of more than two groups/time-
points (e.g., erlotinib long-term treatment experiment), two-way
ANOVA with Bonferroni post-test was applied. For comparison of
survival curves, log-rank (Mantel–Cox) tests were performed. Data
are shown as mean  SEM. A P-value below 0.05 was considered
statistically significant. For analyses and calculation, GraphPad
Prism 6 software was used.
Expanded View for this article is available online.
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